ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
EudraCT number 2020-000348-77
Protocol number XL184-315
Sponsor Exelixis, Inc., 1851 Harbor Bay Parkway, CA 94502 Alameda, United States of America
Indications Oncology
Diagnosis prostate cancer
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2020
Date of approval by Institute (SÚKL) 26.8.2020
Date of approval by EC 14.9.2020
Date of initiation CT in ČR 19.3.2021
Date of ending CT in ČR
Sites Urocentrum Praha s.r.o.,,Karlovo nám. 319/3,Praha ,120 00
Fakultní nemocnice u sv. Anny v Brně,Onkologicko-chirurgické oddělení,Pekařská 53,Brno,656 91
Thomayerova nemocnice,Onkologická klinika 1. LK UK a TN,Vídeňská 800,Praha,140 59
Všeobecná fakultní nemocnice v Praze,Urologická klinika,Ke Karlovu 6,Praha 2,128 00
Nemocnice na Bulovce,Ústav radiační onkologie,Budínova 67/2,Praha 8,180 81
Fakultní nemocnice Olomouc,Onkologická klinika,I.P.Pavlova 6,Olomouc,779 00

‹‹ Back to list